Hims & Hers Health, Inc. (HIMS)
Hims & Hers: There's Opportunity In This Crash (Upgrade)
Hims & Hers offers a compelling "Buy" opportunity after a 30% pullback, despite recent growth concerns and insider selling. HIMS maintains strong long-term growth targets, aiming for $6.5 billion in revenue and $1.3+ billion in adjusted EBITDA by FY30 (representing ~4x profit expansion from current levels). Current valuation appears more attractive, with HIMS trading at 32.8x EV/FY25 adjusted EBITDA and potentially 24.7x by FY26.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.46, marking a -3.85% move from the previous day.
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
HIMS accelerates AI-powered care with new tech leadership, personalized treatments and a major $870 million investment push.
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal 'grey area' regarding compounded obesity drugs. Recent FDA policy changes ending temporary compounding allowances raise questions about HIMS's continued ability to offer these treatments.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Hims & Hers Health, Inc. (HIMS) reached $59.15 at the closing of the latest trading day, reflecting a -5.75% change compared to its last close.
How HIMS Stock Rises To $120?
Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is creating revenue sources beyond its debated compounded GLP-1 obesity treatments. With shares already up 150% year-to-date and trading at approximately $60, the critical question now is: could HIMS stock go up another 2x to $120?
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?
HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.
Hims & Hers: Why I'm Betting On HIMS Heading To $100
I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aiming for 30%+ growth in 2026. Despite a temporary dip into negative free cash flow, HIMS maintains strong profitability targets and trades at an attractive 24x forward free cash flow.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Expands Health Access Through Subscription Revenue Model
HIMS boosts predictable revenue and customer loyalty with a flexible, subscription-based model across key health categories.
Buy HIMS Stock At $56?
Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primarily due to the announcement that a U.S. federal judge dismissed a lawsuit brought by Eli Lilly against a rival telehealth company, Willow Health, on September 2, 2025.
